Sugi Predict

Sugi Predict / Compounds / SCHEMBL832511

SCHEMBL832511

SCHEMBL832511

CC(C)(C)OC(=O)n1cnc2cc(CBr)ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 1/20 0.42
▸ RIPK3 Q9Y572 1/20 0.42
▸ HTR6 P50406 1/20 0.37
▸ ASAH1 Q13510 2/20 0.35
▸ NR1H2 P55055 5/20 0.35
▸ GSK3B P49841 1/20 0.35
▸ GABRG2 P18507 3/20 0.34
▸ GABRB3 P28472 3/20 0.34
▸ GABRA5 P31644 3/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ NR1H3 Q13133 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ GABRA1 P14867 2/20 0.33
▸ GABRA2 P47869 2/20 0.33
▸ GABRA6 Q16445 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28349234 0.94 ASAH1 (0.39) RIPK1RIPK3HTR6ASAH1GSK3B
SCHEMBL832990 0.90 RIPK1 (0.38) RIPK1RIPK3HTR6ASAH1NR1H2
SCHEMBL30847454 0.83 SIK1 (0.44) RIPK1RIPK3HTR6GSK3BGABRG2
SCHEMBL559567 0.83 SIK1 (0.44) RIPK1RIPK3HTR6GSK3BGABRG2
SCHEMBL832377 0.81 GABRG2 (0.44) RIPK1RIPK3HTR6ASAH1GABRG2
SCHEMBL1455275 0.81 HTR6 (0.47) RIPK1RIPK3HTR6GABRG2GABRB3
SCHEMBL25736862 0.81 RIPK1 (0.40) RIPK1RIPK3HTR6ASAH1NR1H2
SCHEMBL2130373 0.80 SIGMAR1 (0.41) RIPK1RIPK3HTR6ALDH1A1KDM4E
SCHEMBL482648 0.80 NR1H2 (0.43) RIPK1RIPK3HTR6NR1H2GABRG2
SCHEMBL4819554 0.80 GABRG2 (0.49) RIPK1RIPK3HTR6GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001873-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2026-01-01 — — US disclosed
US-12384772-B2 Inhibitors VIVORYON THERAPEUTICS N.V. (DE) 2025-08-12 — — US disclosed
CN-117024352-A Novel inhibitors 维沃里翁治疗股份有限公司 2023-11-10 — — CN disclosed
US-11725000-B2 Apoptosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2023-08-15 — — US disclosed
US-11725000-B2 Apoptosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2023-08-15 — — US disclosed
US-11725000-B2 Apoptosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2023-08-15 — — US disclosed
CN-110719910-B Novel inhibitors 维沃里翁治疗股份有限公司 2023-07-21 — — CN disclosed
CN-110023292-B Apoptosis inhibitors 北京生命科学研究所 2022-10-04 — — CN disclosed
US-20220274977-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2022-09-01 — — US disclosed
CN-109563043-B Substituted pyridines as inhibitors of DNMT1 葛兰素史密斯克莱知识产权发展有限公司 2022-05-31 — — CN disclosed
US-20110104110-A1 SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF SHERING CORPORATION 2011-05-05 — — US disclosed
US-20110104110-A1 SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF SHERING CORPORATION 2011-05-05 — — US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 — — US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 — — US disclosed
US-20100322901-A1 5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF SCHERING CORPORATION 2010-12-23 — — US disclosed
US-20100322901-A1 5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF SCHERING CORPORATION 2010-12-23 — — US disclosed
US-20100196319-A1 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS SCHERING CORPORATION (US) 2010-08-05 — — US disclosed
US-20100196319-A1 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS SCHERING CORPORATION (US) 2010-08-05 — — US disclosed
US-20100098661-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS SCHERING CORPORATION 2010-04-22 — — US disclosed
US-20100098661-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS SCHERING CORPORATION 2010-04-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100196319-A1 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS ZC3HAV1, IDO1, ZC3HAV1L RIPK1 611/4885RIPK3 655/4885HTR6 79/4885
US-20260001873-A1 NOVEL INHIBITORS GLS, GLS2, SULT1E1 RIPK1 4630/4885RIPK3 4553/4885HTR6 2427/4885
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 RIPK1 1210/4885RIPK3 581/4885HTR6 25/4885
US-11725000-B2 Apoptosis inhibitors BAX, SDHA, SDHB RIPK1 991/4885RIPK3 574/4885HTR6 3260/4885
US-20110104110-A1 SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF IDO1, IDO2, INMT RIPK1 1577/4885RIPK3 1070/4885HTR6 22/4885
US-20100098661-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS ZC3HAV1, IDO1, ZC3HAV1L RIPK1 768/4885RIPK3 850/4885HTR6 260/4885
US-12384772-B2 Inhibitors GLS, QPCT, GLS2 RIPK1 4765/4885RIPK3 4626/4885HTR6 4009/4885
US-20100322901-A1 5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF IDO1, IDO2, TPH1 RIPK1 750/4885RIPK3 816/4885HTR6 14/4885
US-20220274977-A1 NOVEL INHIBITORS GLUL, GLS, QPCT RIPK1 4160/4885RIPK3 4339/4885HTR6 2778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.